TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15720497

Group type: EXPERIMENTAL
Intervention: Transitional discharge model
Number of subjects: 0
Study: 12053718

Group type: EXPERIMENTAL
Intervention: High dose therapy
Number of subjects: 13

Group type: COMPARATOR
Intervention: BCNU containing American Intergroup study
Number of subjects: 13
Study: 27093747

Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Activated charcoal (15 g)
Number of subjects: 12
Study: 7607713

Group type: EXPERIMENTAL
Intervention: 25 mg losartan + 25 mg hydrochlorothiazide
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: 50 mg losartan + 25 mg hydrochlorothiazide
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: 100 mg losartan + 25 mg hydrochlorothiazide
Number of subjects: 304

Group type: COMPARATOR
Intervention: Placebo + 25 mg hydrochlorothiazide
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: All losartan groups
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 304
Study: 2218421

Group type: EXPERIMENTAL
Intervention: Ofloxacin 400 mg once daily for 10-14 days
Number of subjects: 192

Group type: COMPARATOR
Intervention: Doxycycline 200 mg once daily followed by 100 mg once daily for 10-14 days
Number of subjects: 192
Study: 23338

Group type: EXPERIMENTAL
Intervention: Cimetidine (300 mg)
Number of subjects: 0
Study: 31368998

Group type: EXPERIMENTAL
Intervention: Computational adaptive optics (CAO) using multiple randomized subaperture correlations
Number of subjects: 0
Study: 28455250

Group type: EXPERIMENTAL
Intervention: Parent video education about infant soothing (video)
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Video and oral sucrose solution (sucrose)
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Video and sucrose and topical liposomal lidocaine (lidocaine)
Number of subjects: 352

Group type: COMPARATOR
Intervention: Placebo control (standard care)
Number of subjects: 352
Study: 26266386

Group type: EXPERIMENTAL
Intervention: Sufentanil plus dexmedetomidine (0.02 μg/kg/h sufentanil + 0.05 μg/kg/h dexmedetomidine) (Group D2)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Sufentanil (0.02 μg/kg/h) (Group C)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Sufentanil plus dexmedetomidine (0.02 μg/kg/h sufentanil + 0.02 μg/kg/h dexmedetomidine) (Group D1)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Sufentanil plus dexmedetomidine (Group D1 and D2)
Number of subjects: 90
Study: 24057042

Group type: EXPERIMENTAL
Intervention: Lapatinib (1,250 mg once daily) and Everolimus (5 mg once daily)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Lapatinib and Everolimus combination
Number of subjects: 23
Study: 21945050

Group type: EXPERIMENTAL
Intervention: Hysteroscopic septoplasty (surgery) in group A (A2)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Control group A1 (no surgery)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Control group B1 (no surgery)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Hysteroscopic septoplasty (surgery) in group B (B2)
Number of subjects: 138
Study: 19920721

Group type: EXPERIMENTAL
Intervention: Vibrating cold device
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Vapocoolant
Number of subjects: 30

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 30
Study: 16702318

Group type: EXPERIMENTAL
Intervention: Fish oil (FO) supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Olive oil (OO) supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: High habitual fish intake (HFI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Children's dietary intake of (n‐3) PUFA
Number of subjects: 0
Study: 12716684

Group type: EXPERIMENTAL
Intervention: 4.5 g ALA/d
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 9.5 g ALA/d
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 0.77 g EPA+DHA/d
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 1.7 g EPA+DHA/d
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo (no additional n-3 PUFAs)
Number of subjects: 150
Study: 11036040

Group type: EXPERIMENTAL
Intervention: Delavirdine (DLV) plus zidovudine (AZT)
Number of subjects: 597

Group type: COMPARATOR
Intervention: Zidovudine (AZT)
Number of subjects: 597
Study: 8888669

Group type: EXPERIMENTAL
Intervention: Primary percutaneous transluminal coronary angioplasty
Number of subjects: 0

Group type: COMPARATOR
Intervention: Thrombolytic therapy
Number of subjects: 0
Study: 1345038

Group type: EXPERIMENTAL
Intervention: Pyruvate (36-53 g)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (Polycose, 21-37 g)
Number of subjects: 40
Study: 2863675

Group type: EXPERIMENTAL
Intervention: Chloramphenicol alone
Number of subjects: 748

Group type: COMPARATOR
Intervention: Chloramphenicol plus penicillin
Number of subjects: 748
Study: 31288846

Group type: EXPERIMENTAL
Intervention: PECAN intervention (Participation Enabling CAre in Nursing)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Optimised standard care (control group)
Number of subjects: 129
Study: 31662409

Group type: EXPERIMENTAL
Intervention: Physical activity behaviour change intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Psychoeducation about physical activity
Number of subjects: 0
Study: 26912731

Group type: EXPERIMENTAL
Intervention: QAR-Depression condition
Number of subjects: 51

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 51
Study: 26041131

Group type: EXPERIMENTAL
Intervention: Standard diet recommendations plus free Smartphone application and wearable device
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard diet recommendations alone
Number of subjects: 70
Study: 23524063

Group type: EXPERIMENTAL
Intervention: Executive Functioning (EF) training with game-elements for 6 weeks
Number of subjects: 44

Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 44
Study: 21681921

Group type: EXPERIMENTAL
Intervention: IL-2 therapy infused on days 0-3 and 8-17
Number of subjects: 289

Group type: COMPARATOR
Intervention: No further therapy (AML control group)
Number of subjects: 289
Study: 19500616

Group type: EXPERIMENTAL
Intervention: Subliminal distractor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Supraliminal distractor (control)
Number of subjects: 0
Study: 16689038

Group type: EXPERIMENTAL
Intervention: Education, reminder system, and mechanical toothbrush
Number of subjects: 50

Group type: COMPARATOR
Intervention: Mechanical toothbrush
Number of subjects: 50
Study: 15568932

Group type: EXPERIMENTAL
Intervention: Intraoperatively assessed optical properties using spatially resolved diffuse remittance spectroscopy (DRS)
Number of subjects: 24
Study: 11294480

Group type: EXPERIMENTAL
Intervention: Brofaromine (reversible monoamine oxidase A inhibitor)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9398716

Group type: EXPERIMENTAL
Intervention: Metformin (500 mg, three times daily for 4-6 weeks)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 7639379

Group type: EXPERIMENTAL
Intervention: Heparin
Number of subjects: 10

Group type: COMPARATOR
Intervention: Citrate (ACD)
Number of subjects: 10
Study: 2906017

Group type: EXPERIMENTAL
Intervention: Celiprolol, 400 mg once daily
Number of subjects: 16

Group type: COMPARATOR
Intervention: Atenolol, 100 mg once daily
Number of subjects: 16
Study: 29634375

Group type: EXPERIMENTAL
Intervention: Topical nepafenac 0.1%
Number of subjects: 52
Study: 27148652

Group type: EXPERIMENTAL
Intervention: Caries Classification System (CCS) training
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: International Caries Detection and Assessment System (ICDAS II) training
Number of subjects: 8

Group type: COMPARATOR
Intervention: Visual-tactile (VT) examination
Number of subjects: 8
Study: 24684734

Group type: EXPERIMENTAL
Intervention: Transdermal clonidine (5 mg patch)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 23557068

Group type: EXPERIMENTAL
Intervention: 200 mg udenafil + tamsulosin placebo
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 200 mg udenafil + 0.4 mg tamsulosin
Number of subjects: 27

Group type: COMPARATOR
Intervention: udenafil placebo + 0.4 mg tamsulosin
Number of subjects: 27
Study: 21434580

Group type: EXPERIMENTAL
Intervention: Memantine (20 mg) with buprenorphine placebo
Number of subjects: 45

Group type: COMPARATOR
Intervention: Buprenorphine (2 mg) with memantine placebo
Number of subjects: 45
Study: 19887810

Group type: EXPERIMENTAL
Intervention: Homeopathic remedies (verum)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Quality of life, coping, global assessments of treatment success
Number of subjects: 24
Study: 16501299

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 400

Group type: COMPARATOR
Intervention: Non-amiodarone
Number of subjects: 400
Study: 12740279

Group type: EXPERIMENTAL
Intervention: Percutaneous dilatational tracheostomy (PDT)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Surgical tracheostomy (ST)
Number of subjects: 211
Study: 10770146

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens, 0.625 mg, plus medroxyprogesterone acetate, 2.5 mg, in 1 tablet daily (n = 1380)
Number of subjects: 2763

Group type: COMPARATOR
Intervention: Placebo (n = 1383)
Number of subjects: 2763

Group type: EXPERIMENTAL
Intervention: Estrogen and progestin
Number of subjects: 2763
Study: 9301383

Group type: EXPERIMENTAL
Intervention: mivacurium 84.2 micrograms kg‐1
Number of subjects: 70

Group type: COMPARATOR
Intervention: pancuronium 68.5 micrograms kg‐1
Number of subjects: 70
Study: 8333822

Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Behaviour therapy
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 75
Study: 3591595

Group type: EXPERIMENTAL
Intervention: Terodiline hydrochloride 24 mg once a day for 4 weeks
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Terodiline hydrochloride 12 mg once a day for 4 weeks
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Terodiline hydrochloride (both dosages)
Number of subjects: 95
Study: 28866315

Group type: EXPERIMENTAL
Intervention: Goals of Care (GOC) decision aid intervention
Number of subjects: 11
Study: 27016217

Group type: EXPERIMENTAL
Intervention: Flotation-REST treatment (12 sessions)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 50
Study: 24608453

Group type: EXPERIMENTAL
Intervention: Sulfasalazine with temozolomide and radiation therapy
Number of subjects: 24

Group type: COMPARATOR
Intervention: Temozolomide and radiation therapy (Control)
Number of subjects: 24
Study: 23478632

Group type: EXPERIMENTAL
Intervention: Daily Disposable (DD) contact lenses
Number of subjects: 283

Group type: COMPARATOR
Intervention: Daily Wear with Hydrogen Peroxide (DW-H2O2)
Number of subjects: 283

Group type: COMPARATOR
Intervention: Daily Wear with Multipurpose Solutions (DW-MPS)
Number of subjects: 283
Study: 16020461

Group type: EXPERIMENTAL
Intervention: Exercise on a cycle ergometer for 60 min at 50% of peak oxygen consumption after a meal (M‐‐>E)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Resting conditions before and after a meal (M‐‐>R)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Combination of food intake and exercise
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Exercise and food intake
Number of subjects: 6
Study: 12559641

Group type: EXPERIMENTAL
Intervention: Combined lung cancer prevention agent (specifics not provided)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Study vitamins (specifics not provided)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Follow-up activities planned for disease endpoints and smoking behavior
Number of subjects: 0
Study: 9858113

Group type: EXPERIMENTAL
Intervention: Cortisol (200 mg/day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Dexamethasone (3 mg/day)
Number of subjects: 10
Study: 7596966

Group type: EXPERIMENTAL
Intervention: State Modulation (SM) treatment
Number of subjects: 327

Group type: COMPARATOR
Intervention: State Modulation (SM) combined with PHN or NSTEP‐P
Number of subjects: 327

Group type: COMPARATOR
Intervention: State Modulation (SM) combined with NSTEP‐P
Number of subjects: 327
Study: 2187001

Group type: EXPERIMENTAL
Intervention: Theophylline treatment (two different dosage regimens)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 382149

Group type: EXPERIMENTAL
Intervention: Domperidone (30 mg/day)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Domperidone (30 mg/day) during open phase
Number of subjects: 41
Study: 31297652

Group type: EXPERIMENTAL
Intervention: Teriparatide
Number of subjects: 96

Group type: COMPARATOR
Intervention: Alendronate
Number of subjects: 96
Study: 29278354

Group type: EXPERIMENTAL
Intervention: MiStent SES
Number of subjects: 148

Group type: COMPARATOR
Intervention: Endeavor
Number of subjects: 148
Study: 27475087

Group type: EXPERIMENTAL
Intervention: 100 mg of dasatinib once daily
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: 70 mg of dasatinib twice daily
Number of subjects: 79
Study: 25129979

Group type: EXPERIMENTAL
Intervention: Intramuscular NGF treatment
Number of subjects: 115

Group type: COMPARATOR
Intervention: Control group (intravenous vasodilators, energy mixture, steroid pulse therapy, methylcobalamin neurotrophic therapy)
Number of subjects: 115
Study: 23715562

Group type: EXPERIMENTAL
Intervention: MAGE‐A3 immunotherapy with AS15
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MAGE‐A3 immunotherapy with AS02B
Number of subjects: 0

Group type: COMPARATOR
Intervention: MAGE‐A3 plus AS02B in GS-positive patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo in GS-positive patients
Number of subjects: 0
Study: 20135094

Group type: EXPERIMENTAL
Intervention: Teriparatide (rhPTH (1‐34), TPTD) for 24 months
Number of subjects: 45
Study: 18949181

Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii (500 mg/day) for 12 days
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo for 12 days
Number of subjects: 86
Study: 15843667

Group type: EXPERIMENTAL
Intervention: Gatifloxacin (400 mg daily for 2 weeks, then 10-day course every month for 2 years)
Number of subjects: 4162

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4162

Group type: EXPERIMENTAL
Intervention: Gatifloxacin
Number of subjects: 4162

Group type: COMPARATOR
Intervention: Gatifloxacin and Placebo
Number of subjects: 4162
Study: 12426647

Group type: EXPERIMENTAL
Intervention: Tilt-table testing (TTT) performed in the afternoon first, then in the morning (Group I: 68 patients)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Tilt-table testing (TTT) performed in the morning first, then in the afternoon (Group II: 55 patients)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Tilt-table testing (TTT) performed in the afternoon
Number of subjects: 123

Group type: COMPARATOR
Intervention: Tilt-table testing (TTT) performed in the morning
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Tilt-table testing (TTT) with first negative tests
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Tilt-table testing (TTT) with first positive tests
Number of subjects: 123
Study: 10351964

Group type: EXPERIMENTAL
Intervention: Abciximab (bolus 0.25 mg/kg and 12-hour infusion of 0.125 microg/kg/min)
Number of subjects: 888

Group type: COMPARATOR
Intervention: Accelerated-dose alteplase (100 mg)
Number of subjects: 888

Group type: EXPERIMENTAL
Intervention: Alteplase (50 mg, 15 mg bolus; infusion of 35 mg over 60 minutes) plus abciximab
Number of subjects: 888

Group type: EXPERIMENTAL
Intervention: Alteplase (50 mg, 15 mg bolus; infusion of 35 mg over 60 minutes) plus abciximab and low-dose heparin
Number of subjects: 888

Group type: EXPERIMENTAL
Intervention: Alteplase (50 mg, 15 mg bolus; infusion of 35 mg over 60 minutes) plus abciximab and very-low-dose heparin
Number of subjects: 888

Group type: EXPERIMENTAL
Intervention: Streptokinase (500,000 U to 1.5 MU) plus abciximab
Number of subjects: 888

Group type: COMPARATOR
Intervention: Alteplase alone (n=235)
Number of subjects: 888

Group type: EXPERIMENTAL
Intervention: Abciximab alone (n=32)
Number of subjects: 888

Group type: EXPERIMENTAL
Intervention: Streptokinase plus abciximab (n=143)
Number of subjects: 888
Study: 8824651

Group type: EXPERIMENTAL
Intervention: Psyllium (5 g b.d.)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 2117517

Group type: EXPERIMENTAL
Intervention: Levonorgestrel (L‐Ng, 0.03 mg twice a day for 20 days)
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Ethinylestradiol (EE, 0.05 mg per day for 20 days)
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Ibuprofen (Ib, 800 mg three times a day for 5 days)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Placebo (PL, one pill of lactose for 20 days)
Number of subjects: 183
Study: 7352687

Group type: EXPERIMENTAL
Intervention: Epinephrine 0.1 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Epinephrine (various dosages)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Epinephrine 0.1 mg (repeated administration)
Number of subjects: 0
Study: 30939422

Group type: EXPERIMENTAL
Intervention: Sugammadex (Group S, n = 40) - 2 mg/kg
Number of subjects: 84

Group type: COMPARATOR
Intervention: Neostigmine (Group N, n = 44) - 1 mg neostigmine methylsulfate and 0.2 mg glycopyrrolate
Number of subjects: 84
Study: 28493338

Group type: EXPERIMENTAL
Intervention: gustatory event‐related potentials (gERPs) with five isointense basic tastants presented at a medium level
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: gustatory event‐related potentials (gERPs)
Number of subjects: 96
Study: 26091743

Group type: EXPERIMENTAL
Intervention: Evidence-based training on providing counselling and insertion of IUDs or progestin implants
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1500
Study: 23504679

Group type: EXPERIMENTAL
Intervention: Holmium:YAG laser lithotripsy
Number of subjects: 112

Group type: COMPARATOR
Intervention: Pneumatic lithotripsy
Number of subjects: 112
Study: 21691464

Group type: EXPERIMENTAL
Intervention: Ondansetron 4mg
Number of subjects: 64

Group type: COMPARATOR
Intervention: Prochlorperazine 10mg
Number of subjects: 64
Study: 20137622

Group type: EXPERIMENTAL
Intervention: Transurethral electro-resection as sole modality (investigation group)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Transurethral electro-resection or electric coagulation combined with bladder instillation of anti-tumor drugs (control group)
Number of subjects: 48
Study: 17036169

Group type: EXPERIMENTAL
Intervention: Surgical treatment for stress urinary incontinence
Number of subjects: 655

Group type: EXPERIMENTAL
Intervention: Health and sociodemographic factors
Number of subjects: 655
Study: 15056514

Group type: EXPERIMENTAL
Intervention: Risperidone (0.02-0.06 mg/kg/day, mean dose 1.5 mg/day)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 107
Study: 11822756

Group type: EXPERIMENTAL
Intervention: Topotecan followed by Etoposide (TE group: T on days 1-3 and E on days 4-6)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Etoposide followed by Topotecan (ET group: E on days 1-3 and T on days 4-6)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Topotecan and Etoposide (dose level 3: T/E 1.00/100 mg/m2 and 75 mg/m2 respectively)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Topotecan and Etoposide (TE and ET groups)
Number of subjects: 19
Study: 9715339

Group type: EXPERIMENTAL
Intervention: d-fenfluramine
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 7974314

Group type: EXPERIMENTAL
Intervention: Education centre plus usual follow up
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual follow up
Number of subjects: 0
Study: 2604350

Group type: EXPERIMENTAL
Intervention: Continuous postoperative wound perfusion with 0.5% bupivacaine for 24 h followed by normal saline for a further 24 h
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normal saline perfusion
Number of subjects: 30
Study: 1177348

Group type: EXPERIMENTAL
Intervention: Co-trimoxazole (trimethoprim/sulphamethoxazole, 10 mg trimethoprim/kg/day in two divided daily doses for 10 days)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Chloramphenicol (100 mg/kg/day in four divided daily doses for 10 days)
Number of subjects: 23
Study: 29865924

Group type: EXPERIMENTAL
Intervention: Microfracture or autologous cartilage implantation
Number of subjects: 16
Study: 28607333

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 150
Study: 25372657

Group type: EXPERIMENTAL
Intervention: Problem adaptation therapy (PATH)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Supportive therapy for cognitively impaired patients (ST‐CI)
Number of subjects: 74
Study: 23444096

Group type: EXPERIMENTAL
Intervention: 5RM leg-press re-warm-up
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SSG re-warm-up
Number of subjects: 0

Group type: COMPARATOR
Intervention: CON (passive recovery)
Number of subjects: 0
Study: 21474499

Group type: EXPERIMENTAL
Intervention: CT-detected emphysema severity (measured by Perc15)
Number of subjects: 2085
Study: 19141981

Group type: COMPARATOR
Intervention: Pulmonary artery first-ligation group (PA group)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Pulmonary vein first-ligation group (PV group)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: NSCLC patients compared to benign lung disease and healthy persons
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: NSCLC stage III and lymph node positive
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Distal part of the pulmonary vein
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Preoperation vs. 7 days after operation
Number of subjects: 26
Study: 16189291

Group type: EXPERIMENTAL
Intervention: Tolvaptan (30 mg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Furosemide (80 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 14767420

Group type: EXPERIMENTAL
Intervention: Submaximal exercise at 2325 m above sea level
Number of subjects: 10

Group type: COMPARATOR
Intervention: Submaximal exercise at 690 m above sea level
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Submaximal exercise
Number of subjects: 10